Самое главное, что после прочтения книги вы не будете фанатично лишать себя еды из-за устаревших рекомендаций диеты № 5 и будете подбирать питание и способы приготовления пищи, исходя из их реальной пользы и вреда для печени. А в идеале уже сейчас начнете питаться так, чтобы печень оставалась в первозданном состоянии на долгие годы.
Нужно помнить, что печень – не дерево, посадишь – не вырастет.
Поэтому берегите печень и будьте здоровы!
Об авторе
«В клинике лечение не должно превращаться в процесс, оно всегда должно приносить результат. Причина многих неудач со здоровьем – непонимание работы организма».
Доктор Вялов Сергей Сергеевич – опытный гастроэнтеролог, гепатолог, кандидат медицинских наук. Автор более 160 научных статей, в том числе около 20 зарубежных книг для врачей и пациентов. 12-е место в рейтинге Comcon research среди врачей-экспертов. Руководитель федеральных образовательных программ. Инстаграм-блогер @DoctorVyalov.
Международное партнерство и членство в ассоциациях:
• AGA – Американская гастроэнтерологическая ассоциация,
• UEG – Европейская гастроэнтерологическая ассоциация,
• EASL – Европейское общество по изучению печени.
Автор образовательного курса «Просто Про Пищеварение», созданного с использованием технологий дополненной реальности. «Мы не даем решение, мы даем понимание. Вы понимаете сами, и решение становится очевидным».
Сергей Вялов курирует открытый проект для пациентов «Наболевшие вопросы», где все желающие получают ответы бесплатно. Официальный сайт: www.vyalov.com.
Список использованной литературы
1. Guy C.D., Suzuki A., Zdanowicz M. et al. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease. Hepatology. 2012 Jun. 55 (6): 1711–1721.
2. Adams L.A., Lymp J.F., St Sauver J. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul. 129 (1): 113–121.
3. Yeh M.M., Brunt E.M. Pathological features of fatty liver disease. Gastroenterology. 2014 Oct. 147 (4): 754–764.
4. Chalasani N., Younossi Z., Lavine J.E. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan. 67 (1): 328–357.
5. Kim D., Choi S.Y., Park E.H. et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012 Aug. 56 (2): 605–613.
6. Garcia-Galiano D., Sanchez-Garrido M.A., Espejo I. et al. IL-6 and IGF-1 are independent prognostic factors of liver steatosis and non-alcoholic steatohepatitis in morbidly obese patients. Obes Surg. 2007 Apr. 17 (4): 493–503.
7. Promrat K., Kleiner D.E., Niemeier H.M. et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010 Jan. 51 (1): 121–129.
8. Yamamoto M., Iwasa M., Iwata K. et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007 Apr. 22 (4): 498–503.
9. Kistler K.D., Brunt E.M., Clark J.M., Diehl A.M., Sallis J.F., Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011 Mar. 106 (3): 460–468; quiz 469.
1. Casanova J., Bataller R. Alcoholic hepatitis: prognosis and treatment. Gastroenterol Hepatol. 2014 Apr. 37 (4): 262–268.
2. [Guideline] O’Shea R.S., Dasarathy S., McCullough A.J. Alcoholic liver disease. Hepatology. 2010 Jan. 51 (1): 307–328.
3. [Guideline] Singal A.K., Bataller R., Ahn J., Kamath P.S., Shah V.H. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018 Feb. 113 (2): 175–194.
4. Mihas A.A., Tavassoli M. Laboratory markers of ethanol intake and abuse: a critical appraisal. Am J Med Sci. 1992 Jun. 303 (6): 415–428.
5. Lucey M.R. Management of alcoholic liver disease. Clin Liver Dis. 2009 May. 13 (2): 267–275.
6. Rahimi E, Pan JJ. Prognostic models for alcoholic hepatitis. Biomark Res. 2015 Jul 21. 3: 20.
7. Llopis M., Cassard A.M., Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016 May. 65 (5): 830–839.
8. Mitchell M.C., Friedman L.S., McClain C.J. Medical management of severe alcoholic hepatitis: expert review from the Clinical Practice Updates Committee of the AGA Institute. Clin Gastroenterol Hepatol. 2017 Jan. 15 (1): 5–12.
1. [Guideline] Lee W.M., Larson A.M., Stravitz R.T. AASLD position paper: the management of acute liver failure: update 2011. Hepatology.
2. Khandelwal N., James L.P., Sanders C., Larson A.M., Lee W.M. Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology. 2011 Feb. 53 (2):567-76.
3. Alempijevic T., Zec S., Milosavljevic T. Drug-induced liver injury: do we know everything? World J Hepatol. 2017 Apr 8. 9 (10):491–502.
4. Marrone G., Vaccaro F.G., Biolato M. et al. Drug-induced liver injury 2017: the diagnosis is not easy but always to keep in mind. Eur Rev Med Pharmacol Sci. 2017 Mar. 21 (1 Suppl):122-34.
5. Lo Re V. 3rd, Haynes K., Forde K.A. et al. Risk of acute liver failure in patients with drug-inducedliver injury: evaluation of Hy’s law and a new prognostic model. Clin Gastroenterol Hepatol. 2015 Dec. 13 (13): 2360–2368.
6. [Guideline] Chalasani N.P. Hayashi P.H., Bonkovsky H.L., Navarro V.J., Lee W.M., Fontana R.J. et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol. 2014 Jul. 109 (7): 950–966; quiz 967.
7. Stine J.G., Lewis J.H. Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review. Expert Rev Gastroenterol Hepatol. 2016. 10 (4): 517–536.
1. Aggarwal R., Goel A. Hepatitis A: epidemiology in resource-poor countries. Curr Opin Infect Dis. 2015 Oct. 28(5): 488–496.
2. Worns M.A., Teufel A., Kanzler S. et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol. 2008 Jan. 103 (1): 138–146.
3. Kanda T., Nakamoto S., Wu S. et al. Direct-acting antivirals and host-targeting agents against the hepatitis A virus. J Clin Transl Hepatol. 2015 Sep 28. 3(3): 205–210.
4. Linder K.A., Malani P.N. Hepatitis A. JAMA. 2017 Dec 19. 318 (23): 2393.
5. Kamar N., Bendall R., Legrand-Abravanel F. et al. Hepatitis E. Lancet. 2012 Jun 30. 379 (9835): 2477–2488.
6. Hoofnagle J.H., Nelson K.E., Purcell R.H. Hepatitis E. N Engl J Med. 2012 Sep 27. 367 (13): 1237–1244.
7. Mushahwar I.K. Hepatitis E virus: molecular virology, clinical features, diagnosis, transmission, epidemiology, and prevention. J Med Virol. 2008 Apr. 80 (4): 646–658.
8. Nelson K.E., Heaney C.D., Labrique A.B., Kmush B.L., Krain L.J. Hepatitis E: prevention and treatment. Curr Opin Infect Dis. 2016 Oct. 29 (5): 478–485.
9. Wedemeyer H., Pischke S., Manns M.P. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology. 2012 May. 142 (6): 1388–1397.e1.
10. Debing Y., Moradpour D., Neyts J., Gouttenoire J. Update on hepatitis E virology: Implications for clinical practice. J Hepatol. 2016 Jul. 65(1): 200–212.
11. [Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis E virus infection. J Hepatol. 2018 Jun. 68 (6): 1256–1271.
12. [Guideline] American Association for the Study of Liver Diseases, Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Updated: May 24, 2018.
13. [Guideline] World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva, Switzerland: World Health Organization. July 2018.
14. Sterling R.K., Bralow S. Extrahepatic manifestations of hepatitis C virus. Curr Gastroenterol Rep. 2006 Feb. 8 (1): 53–59.
15. Kamili S., Drobeniuc J., Araujo A.C., Hayden T.M. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012 Jul. 55 suppl 1: S43–438.
16. Yang D.H, Ho L.J, Lai J.H. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. World J Gastroenterol. 2014 Mar 21. 20 (11): 2962–2970.
17. Omar H., E.l. Akel W., Elbaz T. et al. Generic daclatasvir plus sofosbuvir, with or without ribavirin, in treatment of chronic hepatitis C: real-world results from 18 378 patients in Egypt. Aliment Pharmacol Ther. 2018 Feb. 47 (3): 421–431.
18. Shahid I., AlMalki W.H., Hassan S., Hafeez M.H. Real-world challenges for hepatitis C virus medications: a critical overview. Crit Rev Microbiol. 2018 Mar. 44 (2): 143–160.
19. Te H.S., Jensen D.M. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010 Feb. 14 (1): 1–21, vii.
20. Kuo A., Gish R. Chronic hepatitis B infection. Clin Liver Dis. 2012 May. 16 (2): 347–369.
21. Lau J.Y., Wright T.L. Molecular virology and pathogenesis of hepatitis B. Lancet. 1993 Nov 27. 342 (8883): 1335–1340.
22. [Guideline] Terrault N.A., Lok A.S.F., McMahon B.J. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.